title: Short-term effects of three continuous hormone replacement therapy regimens on platelet tritiated imipramine binding and mood scores: a prospective randomized trial.
abstract: OBJECTIVE
  To evaluate the effects of continuous hormone replacement therapy (HRT) regimens on platelet-tritiated ((3)H-) imipramine binding (Bmax) and mood.
  
  
  METHODS
  Prospective randomized study.
  
  
  METHODS
  University hospital.
  
  
  METHODS
  Sixty postmenopausal patients.
  
  
  METHODS
  Randomization to 3 months of daily treatment with tibolone and conjugated equine estrogen (CEE).625 mg combined either with 2.5 or 5 mg of medroxyprogesterone acetate (MPA). The inclusion criteria-matched patients declined for HRT were prescribed daily alendronate. Pre- and posttreatment blood sampling for Bmax and mood evaluation with the Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were done.
  
  
  METHODS
  Pre- and posttreatment Bmax and mood scores.
  
  
  RESULTS
  As compared with baseline, both CEE+MPA regimens and tibolone significantly increased Bmax. The comparisons of percent change from baseline Bmax for the CEE+MPA and tibolone groups were similar. All three HRT regimens improved the BDI significantly, while there were no significant changes in the STAI. In the alendronate group, there were no significant changes in both pre- and posttreatment Bmax and mood scores.
  
  
  CONCLUSIONS
  Continuous treatment with CEE+MPA and tibolone increases platelet (3)H-imipramine binding and improves mood. Mood-enhancing effects of tibolone may occur through the serotonergic system, as is the case with estrogen.
authors: Department of Obstetrics and Gynecology, Hacettepe University School of Medicine, Ankara, Turkey. bukulmez@hacettepe.edu.tr
authors: O
authors: O
authors: Bukulmez
authors: A
authors: A
authors: Al
authors: H
authors: H
authors: Gurdal
authors: H
authors: H
authors: Yarali
authors: B
authors: B
authors: Ulug
authors: T
authors: T
authors: Gurgan
mesh_terms: D000339:Affect; D019386:Alendronate / Q000494:pharmacology; D001007:Anxiety; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D004958:Estradiol / Q000097:blood; D015914:Estrogen Replacement Therapy / Q000523:psychology; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005260:Female; D006801:Humans; D007099:Imipramine / Q000097:blood*; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology; D008875:Middle Aged; D009652:Norpregnenes / Q000494:pharmacology; D017698:Postmenopause; D011446:Prospective Studies; D014316:Tritium
chemical_list: D004966:Estrogens, Conjugated (USP); D009652:Norpregnenes; D014316:Tritium; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; C027385:tibolone; D007099:Imipramine; D019386:Alendronate